The question of whether Longboard Pharmaceuticals is still in business can be answered by examining recent events. Longboard Pharmaceuticals was acquired by Lundbeck.
Table of contents
Acquisition Details
The acquisition significantly enhances Lundbeck’s neuroscience pipeline. The deal was expected to close in the fourth quarter of 2024, pending standard closing conditions, including regulatory approvals and tender of a majority of Longboard’s outstanding shares.
Recent Developments
Longboard Pharmaceuticals reported their Third Quarter 2024 financial results and provided corporate updates in conjunction with Lundbeck.
Historical Context
Prior to the acquisition, Longboard Pharmaceuticals focused on developing novel medicines for neurological diseases. They had ongoing clinical trials, such as the Phase 1b/2a PACIFIC Study for LP352 in developmental and epileptic encephalopathies (DEEs). Additionally, they were working on LP659 and had planned an IND submission.
While Longboard Pharmaceuticals, as an independent entity, is no longer operating, its assets and pipeline have been integrated into Lundbeck. Therefore, its legacy continues within Lundbeck’s operations.
сегодня
Impact on Pipeline
The acquisition means that Lundbeck now controls the future of Longboard’s developmental drugs, including LP352 and LP659. The progress of these drugs will be reported as part of Lundbeck’s overall pipeline updates.
Future of Longboard’s Research
The research and development efforts previously underway at Longboard are now likely integrated into Lundbeck’s existing research infrastructure. This could lead to accelerated development timelines or changes in strategic direction for the acquired assets.
Implications for Investors
Former Longboard Pharmaceuticals shareholders will have received consideration as part of the acquisition agreement. The specific details of the consideration would be outlined in the official transaction documents.
